NCT06850714View on ClinicalTrials.gov

Evaluation of Bifidobacterium Breve PRL2020 in Preventing Antibiotic-Associated Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid

NANot yet recruitingINTERVENTIONAL

Enrollment

800

Participants

Timeline

Start Date

February 23, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Antibiotic Side Effect

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium breve PRL2020 (Brevicillin®)

Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) at a dose of 20 billion CFU per day (one stick in the morning and one in the evening).

DRUG

Amoxicillin or Amoxicillin/Clavulanic Acid

Treatment of Amoxicillin or Amoxicillin/Clavulanic Acid as per medical prescription.

Trial Locations (1)

Unknown

Medicine & Technological Innovation Dept. University of Insubria, Varese

All Listed Sponsors

collaborator

Università degli Studi dell'Insubria

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER

NCT06850714 - Evaluation of Bifidobacterium Breve PRL2020 in Preventing Antibiotic-Associated Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid | Biotech Hunter | Biotech Hunter